An Open-Label, Phase 1/1b Study of ORIC-944 As a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer
Latest Information Update: 01 Oct 2024
At a glance
- Drugs ORIC-944 (Primary)
- Indications Neuroendocrine carcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors ORIC Pharmaceuticals
- 26 Sep 2024 Planned number of patients changed from 42 to 250.
- 26 Sep 2024 Planned End Date changed from 1 Jun 2024 to 1 Sep 2026.
- 26 Sep 2024 Planned primary completion date changed from 1 May 2023 to 1 Dec 2024.